FitzGerald had begun reporting his findings at conferences in 1997, a year before approval of the first COX-2 inhibitor, Celebrex.
As early as 1997, Fitzgerald reported his findings at an academic conference, one year before the approval of the first COX-2 inhibitor Celebrex.
The selective inhibitor of COX-2 has a wide future in the prophylactic-therapeutics of tumor, but many problems need to be solved in future.
Selective COX-2 inhibitors have broad prospects for the prevention and treatment of tumors, and there are still many problems to be further studied.
Unfortunately, cardiovascular side-effects have recently been reported in patients using another selective COX-2 inhibitor, rofecoxib.
Recently, however, there have been reports of cardiovascular side effects in patients treated with another selective COX-2 inhibitor, rofecoxib.
The selective inhibitor of COS-2 is a more ideal method in prophylactic-therapeutics of tumor.
Selective COX-2 inhibitor is an ideal method for tumor prevention and treatment.
Objective: To synthesize valdecoxib, a COX-2 inhibitor.
Objective: To synthesize valdecoxib, a COX-2 inhibitor.
Prophylactic Effect of a Selective COX-2 Inhibitor Celecoxib on Carcinogen-induced Gastric Premalignant Lesions in Rats
The Study of Celecoxib, a Selective COX-2 Inhibitor, on Prevention of Gastric Precancerous Lesions and Its Mechanism
Apoptosis of gastric cancer SGC-7901 cells induced by selective COX-2 inhibitor celecoxib and its relationship with mitochondrial pathway
Cyclooxygenase-2 inhibitor Celebrex induces apoptosis and mitochondrial pathway in gastric cancer SGC-7901 cells
COX-2 inhibitor (Aspirin) inhibited proliferation and induced apoptosis of human esophageal carcinoma in vitro
COX-2 inhibitor (aspirin) inhibits the growth and induces apoptosis of human esophageal cancer cells in vitro
Toxicity of selective COX-2 inhibitor celecoxib on non-small cell lung cancer cell lines and the molecular mechanism in vitro
Study on the Toxicity and Molecular Mechanism of Selective COX-2 Inhibitors on Non small Cell Lung Cancer Cell Lines
Effects of COX-2 inhibitor with cisplatin on proliferation and apoptosis of pancreatic cancer cells
Effect of COX-2 inhibitor combined with cisplatin on proliferation and apoptosis of pancreatic cancer cells